CCA
NBIX icon

Catalyst Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Catalyst Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,800
Closed -$1.11M – 397
2025
Q4 		$1.11M Buy
+7,800
New +$1.13M 0.02% 136

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Capital Advisors's NBIX Position: Q1 2026 in Review

Catalyst Capital Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 7,800 shares — an estimated $1.11M sold.

Catalyst Capital Advisors first reported a position in NBIX in Q4 2025 and held it in 1 quarter. The position peaked at $1.11M in Q4 2025. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Catalyst Capital Advisors reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Catalyst Capital Advisors sold 7,800 Neurocrine Biosciences shares in Q1 2026, an estimated $1.11M.
  • Catalyst Capital Advisors first reported a position in Neurocrine Biosciences in Q4 2025 and held it in 1 quarter.
  • Catalyst Capital Advisors's Neurocrine Biosciences position peaked at $1.11M in Q4 2025.
  • 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Catalyst Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.